SCHEMBL2988115

SCHEMBL2988115

NNC(=O)/C=C/c1cccnc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.67
NPC1 O15118 2/20 0.67
MAPT P10636 2/20 0.67
KDM4E B2RXH2 2/20 0.67
JUN P05412 1/20 0.67
NFKB1 P19838 1/20 0.67
MAPK1 P28482 1/20 0.67
GPR55 Q9Y2T6 1/20 0.67
PFKFB3 Q16875 1/20 0.58
KMT2A Q03164 1/20 0.55
NAMPT P43490 9/20 0.54
ALDH1A1 P00352 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
CYP1A1 P04798 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP1B1 Q16678 2/20 0.52
APAF1 O14727 1/20 0.52
POLB P06746 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2988119 1.00 RAB9A (0.67) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL12425756 0.85 RAB9A (0.69) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL10118164 0.83 RAB9A (0.67) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL5083055 0.83 RAB9A (0.67) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL28438967 0.82 ALDH1A1 (0.76) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL28431765 0.82 ALDH1A1 (0.76) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL5436350 0.81 RAB9A (0.59) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL5436343 0.81 RAB9A (0.59) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL83322 0.81 RAB9A (0.73) RAB9ANPC1MAPTKDM4EJUN
SCHEMBL83267 0.81 RAB9A (0.73) RAB9ANPC1MAPTKDM4EJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed
US-4711892-A Certain 5-nitro-2-furyl derivatives of pyridylpropenoic acid hydrazides which are useful in treating bacterial, fungal, protozoal, parasitic and intestinal infections SYNTHELABO (FR) 1987-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB RAB9A 4462/4885NPC1 261/4885MAPT 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.